FDA clears IND for Century's CNTY-101 in systemic lupus erythematosus

Century Therapeutics, Inc.

FDA notified Century that Phase 1 trial of CNTY-101 may proceed in moderate-to-severe SLE patients who failed ≥2 immunosuppressive therapies.
This is the second IND clearance for CNTY-101 and first in autoimmune/inflammatory disease; previous IND for B-cell malignancies.
Trial expected to start H1 2024 with initial data by year-end 2024; evaluates safety, tolerability, PK, clinical response.
CNTY-101 is an allogeneic iPSC-derived NK cell with 6 genetic edits including CD19 CAR, Allo-Evasion, IL-15, and safety switch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.